Free Trial

Viking Therapeutics (NASDAQ:VKTX) Trading Down 5.5%

Viking Therapeutics logo with Medical background

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report)'s stock price was down 5.5% during trading on Tuesday . The stock traded as low as $49.15 and last traded at $49.26. Approximately 1,472,492 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 4,868,611 shares. The stock had previously closed at $52.12.

Analyst Upgrades and Downgrades

Several equities analysts have commented on VKTX shares. Truist Financial restated a "buy" rating and issued a $120.00 price target on shares of Viking Therapeutics in a research note on Monday, June 17th. Maxim Group restated a "buy" rating and issued a $120.00 price target on shares of Viking Therapeutics in a research note on Tuesday, June 4th. Oppenheimer boosted their price target on shares of Viking Therapeutics from $116.00 to $138.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 26th. Raymond James reiterated a "strong-buy" rating on shares of Viking Therapeutics in a research note on Tuesday, June 4th. Finally, BTIG Research boosted their target price on shares of Viking Therapeutics from $100.00 to $125.00 and gave the stock a "buy" rating in a research note on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Viking Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $112.38.

Check Out Our Latest Stock Analysis on VKTX

Viking Therapeutics Stock Down 8.3 %

The firm has a fifty day simple moving average of $64.64 and a 200-day simple moving average of $50.82. The company has a market cap of $5.27 billion, a PE ratio of -52.52 and a beta of 1.05.


Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. During the same period in the previous year, the business posted ($0.25) EPS. Equities research analysts forecast that Viking Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Viking Therapeutics

In other news, COO Marianna Mancini sold 281,425 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the completion of the sale, the chief operating officer now owns 348,508 shares in the company, valued at $27,413,639.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Greg Zante sold 66,756 shares of the firm's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $74.69, for a total value of $4,986,005.64. Following the completion of the sale, the chief financial officer now owns 174,854 shares in the company, valued at $13,059,845.26. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Marianna Mancini sold 281,425 shares of the firm's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the completion of the sale, the chief operating officer now owns 348,508 shares of the company's stock, valued at approximately $27,413,639.28. The disclosure for this sale can be found here. Insiders own 4.70% of the company's stock.

Institutional Investors Weigh In On Viking Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV acquired a new stake in Viking Therapeutics in the first quarter valued at about $25,000. Lindbrook Capital LLC lifted its position in shares of Viking Therapeutics by 370.7% during the 1st quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 278 shares during the period. Wetzel Investment Advisors Inc. acquired a new stake in shares of Viking Therapeutics during the 4th quarter valued at approximately $37,000. LifeSteps Financial Inc. acquired a new stake in shares of Viking Therapeutics during the 1st quarter valued at approximately $37,000. Finally, Spire Wealth Management acquired a new stake in shares of Viking Therapeutics during the 1st quarter valued at approximately $61,000. Institutional investors and hedge funds own 76.03% of the company's stock.

About Viking Therapeutics

(Get Free Report)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Featured Articles

Should you invest $1,000 in Viking Therapeutics right now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines